Skip to main content

Megan A. Baumgart, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-9319

Fax: (585) 784-7907

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



I chose the field of oncology because I want to help patients through one of the most difficult experiences a person can have.

Cancer treatment requires a team approach involving the patient, medical oncologist, nurses and support staff, as well as other medical teams such as radiation oncology and surgery who are often part of a patient's care. I work with patients to help them understand the overall treatment plan – especially the role of chemotherapy in the treatment of their disease – and support them throughout the course of treatment.

I am optimistic about the future of cancer treatment and want to work towards finding new and better treatment strategies for lung and head and neck cancers through the development of our clinical trials program. We currently have several clinical trials evaluating the role of immunotherapy for the treatment of metastatic head and neck cancers open for enrollment, as well as other clinical trials focused on answering important questions regarding the management of these diseases.

Conditions I Treat

- Small cell lung cancer
- Non-small cell lung cancer
- Head and neck cancers
- Thyroid cancer




    MD | Albany Medical College

    Post-doctoral Training & Residency

    07/01/2011 - 06/30/2014
    Fellowship in Medical Oncology at Yale New Haven Hospital

    07/01/2008 - 06/30/2010
    Residency in Internal Medicine at Rhode Island Hospital GME

    06/20/2007 - 06/30/2008
    Internship in Internal Medicine at Rhode Island Hospital GME

    VIEW ALL expand_more


    2019 - Present
    Early Career Women Faculty Leadership Development Seminar
    Sponsor: AAMC Application Selection Committee

    Annual Award for Outstanding Oncology Research
    Sponsor: Yale University Medical Oncology and Hematology Fellowship
    Location: New Haven, CT

    Albany Medical College- Distinction in Biomedical Ethics
    Location: Albany, NY

    VIEW ALL expand_more


    Journal Articles

    Baumgart, M.; Bazhenova, L.; Haggstrom, D.; Baranda, J.; Belani, C. "PUB031 PRIMAL: A Phase 1b Study of PEGPH20 plus Docetaxel in Patients with Previously Treated Hyaluronan (HA)-High Advanced NSCLC". Journal of Thoracic Oncology. 2017; 12(1): S1465.

    Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN. "Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors." Cancer.. 2015 Jun 1; 121(11):1817-26. Epub 2015 Feb 03.

    Baumgart, M. "New molecular targets on the horizon in non-small cell lung cancer" . American Journal of Hematology and Oncology. 2015; 11(6): 10-13.



    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.